Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study. … [Read more...]
GSK’s shingles vaccine Shingrix succeeds in phase 3 revaccination trial
GSK’s shingles vaccine candidate Shingrix (HZ/su) met its primary objective of inducing a strong immune response in older patients in a phase 3 revaccination trial. … [Read more...]
ImmunoCellular to suspend patient randomization in ICT-107 phase 3 trial
ImmunoCellular Therapeutics has provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma. … [Read more...]
Rubius Therapeutics raises $120m to advance red blood cell technology
Rubius Therapeutics, which is developing red-cell therapeutics (RCTs) as a new class of medicines to address a range of indications, has raised $120m in a highly oversubscribed private financing. … [Read more...]
Shire gets FDA approval for ADHD drug Mydayis
Shire has secured approval from the US Food and Drug Administration (FDA) for its Mydayis (mixed salts of a single-entity amphetamine product) to control attention deficit hyperactivity disorder (ADHD) in patients 13 years and older. … [Read more...]